These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29989000)

  • 1. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.
    Fenoglio R; Sciascia S; Beltrame G; Mesiano P; Ferro M; Quattrocchio G; Menegatti E; Roccatello D
    Oncotarget; 2018 Jun; 9(48):28799-28804. PubMed ID: 29989000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J; Zhao H; Li X; Qian R; Gao P; Lu S; Ma Z
    BMC Nephrol; 2023 Apr; 24(1):112. PubMed ID: 37101300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of rituximab in adult frequently relapsing minimal change disease.
    King C; Logan S; Smith SW; Hewins P
    Clin Kidney J; 2017 Feb; 10(1):16-19. PubMed ID: 28638601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.
    Niu XL; Hao S; Wang P; Zhang W; Guo GM; Wu Y; Kuang XY; Zhu GH; Huang WY
    Biomed Rep; 2016 Aug; 5(2):237-242. PubMed ID: 27446549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
    Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
    Taguchi S; Ohtake T; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
    Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.
    Ren H; Lin L; Shen P; Li X; Xie J; Pan X; Zhang W; Chen N
    Oncotarget; 2017 Nov; 8(55):93438-93443. PubMed ID: 29212162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
    Papakrivopoulou E; Shendi AM; Salama AD; Khosravi M; Connolly JO; Trompeter R
    Nephrology (Carlton); 2016 Oct; 21(10):893-900. PubMed ID: 26860320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?
    Kannan L
    Cureus; 2022 Feb; 14(2):e22313. PubMed ID: 35350528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
    Hoxha E; Stahl RA; Harendza S
    Clin Nephrol; 2011 Aug; 76(2):151-8. PubMed ID: 21762648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.
    Kisner T; Burst V; Teschner S; Benzing T; Kurschat CE
    Nephron Clin Pract; 2012; 120(2):c79-85. PubMed ID: 22286071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in Steroid-Dependent Podocytopathies.
    Costa C; Antunes A; Oliveira J; Pereira M; Godinho I; Fernandes P; Jorge S; Lopes JA; Gameiro J
    Glomerular Dis; 2024; 4(1):129-136. PubMed ID: 39144474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
    Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
    Huang J; Du J; Wang S; Xiao L; Zhao X
    Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.
    Xue C; Yang B; Xu J; Zhou C; Zhang L; Gao X; Dai B; Yu S; Mao Z; Mei C; Xu C
    Clin Kidney J; 2021 Apr; 14(4):1042-1054. PubMed ID: 34094516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells.
    Webendörfer M; Reinhard L; Stahl RAK; Wiech T; Mittrücker HW; Harendza S; Hoxha E
    Front Immunol; 2020; 11():586012. PubMed ID: 33628202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of rituximab with or without glucocorticoid in inducing remission of MCD with different clinical presentations in adults: a retrospective study.
    Sun Y; Li Z; Sun J; Zhang S; Wang R; Chen B
    Clin Kidney J; 2024 Jun; 17(6):sfae139. PubMed ID: 38854425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature.
    Van Horebeek I; Knops N; Van Dyck M; Levtchenko E; Mekahli D
    Acta Clin Belg; 2017 Jun; 72(3):147-155. PubMed ID: 27409338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Barreca A; Fenoglio R; Baldovino S; Menegatti E
    Am J Nephrol; 2017; 46(2):108-113. PubMed ID: 28700988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.